$169 Million is the total value of Tamarack Advisers, LP's 38 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 171.4% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $15,950,000 | +30.4% | 1,250,000 | +29.5% | 9.31% | +21.8% |
NKTR | Buy | NEKTAR THERAPEUTICSequity | $11,535,000 | -1.7% | 590,000 | +18.0% | 6.73% | -8.2% |
LH | Buy | LABORATORY CRP OF AMER HLDGSequity | $10,482,000 | +52.2% | 68,000 | +41.7% | 6.12% | +42.2% |
LNTH | Buy | LANTHEUS HOLDINGS INCequity | $6,795,000 | +87.0% | 385,000 | +32.4% | 3.97% | +74.7% |
TVTY | New | TIVITY HEALTH INCequity | $6,185,000 | – | 155,215 | +100.0% | 3.61% | – |
XRAY | New | DENTSPLY SIRONA INCequity | $4,993,000 | – | 77,000 | +100.0% | 2.92% | – |
SRCL | Buy | STERICYCLE INCequity | $4,579,000 | +85.4% | 60,000 | +101.3% | 2.67% | +73.2% |
MDT | New | MEDTRONIC PLCequity | $3,994,000 | – | 45,000 | +100.0% | 2.33% | – |
NXTM | Buy | NXSTAGE MEDICAL INCequity | $3,196,000 | +8.3% | 127,500 | +15.9% | 1.87% | +1.2% |
SCI | New | SERVICE CORP INTERNATIONALequity | $1,840,000 | – | 55,000 | +100.0% | 1.07% | – |
OPHT | Buy | OPHTHOTECH CORPequity | $1,600,000 | -7.2% | 625,000 | +32.7% | 0.93% | -13.3% |
New | ISHARES TR RUSSELL 2000 ETF US 09/15/17 P140put | $690,000 | – | 2,000 | +100.0% | 0.40% | – | |
New | SPDR S&P 500 ETF TR US 08/18/17 P235put | $326,000 | – | 4,000 | +100.0% | 0.19% | – | |
New | COCA COLA CO US 08/18/17 P46put | $134,000 | – | 1,000 | +100.0% | 0.08% | – | |
New | BROOKDALE SENIOR LIVING INC US 07/21/17 C16call | $106,000 | – | 2,000 | +100.0% | 0.06% | – | |
New | SPECTRANETICS CORP US 10/20/17 C40call | $89,000 | – | 7,752 | +100.0% | 0.05% | – | |
New | BOSTON SCIENTIFIC CORP US 07/21/17 P28put | $55,000 | – | 886 | +100.0% | 0.03% | – | |
New | QUEST DIAGNOSTICS INC US 07/21/17 P110put | $39,000 | – | 376 | +100.0% | 0.02% | – | |
New | PATTERSON COMPANIES INC US 07/21/17 P44put | $4,000 | – | 300 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-08
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VERADIGM ORD | 32 | Q3 2023 | 13.9% |
STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
ATRICURE ORD | 29 | Q3 2023 | 7.6% |
PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
HOLOGIC INC | 17 | Q1 2022 | 6.5% |
SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
Correvio Pharma Corp. | February 15, 2019 | ? | ? |
Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-09 |
13F-HR | 2023-11-16 |
13F-HR | 2023-08-10 |
SC 13D/A | 2023-06-22 |
13F-HR | 2023-05-11 |
13F-HR | 2023-02-13 |
SC 13D/A | 2022-12-01 |
13F-HR | 2022-11-15 |
13F-HR | 2022-08-16 |
13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.